Garrett M. Brodeur, MD

Garrett M. Brodeur, MD, is the director of the Cancer Predisposition Program at CHOP, and associate director of the Abramson Cancer Center at Penn. He has a special interest in the molecular biology, genetics and targeted therapy of neuroblastoma.

Areas of Expertise: Cancer Predisposition in Children and Adolescents, Neuroblastoma
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Background

    Garrett M. Brodeur, MD, is associate chair for Research in Pediatrics, as well as professor of Pediatrics at the University of Pennsylvania and adjunct professor at The Wistar Institute in Philadelphia.

    Dr. Brodeur is a graduate of the Washington University School of Medicine in St. Louis, Missouri, where he completed his pediatric residency. He continued his specialty training with a fellowship in pediatric hematology-oncology at St. Jude’s Children’s Research Hospital in Memphis. He  returned to Washington University for a post-doctoral fellowship in molecular genetics in 1981, and he joined the faculty at CHOP in 1993.

    Dr. Brodeur maintains a special interest in the biology, genetics and treatment of neuroblastoma, the most common solid tumor in childhood, and is internationally recognized for his work in this area. He is currently studying certain genes, proteins and pathways that play important roles in the development and progression of neuroblastomas. For example, he is looking for a tumor suppressor gene on the short arm of chromosome 1 that is frequently deleted or inactivated in aggressive neuroblastomas. He is also examining the role that TRK (pronounced “track”) receptors play in these tumors. TRK-A is expressed on the surface of favorable neuroblastomas that are prone to regress, differentiate or respond well to modest treatment. TRK-B is expressed on the more aggressive neuroblastomas, particularly those that also amplify the MYCN proto-oncogene (a very high risk feature). Finally, he is evaluating a novel drug that can block the function of either TRK-A or TRK-B, and this causes cells expressing these receptors to die by a cellular “suicide”.

    Recently, he has been invited to give lectures on his work at the National Institutes of Health/National Cancer Institute in Bethesda, Maryland; at Kyushu University in Japan, at Washington University in St. Louis, Missouri, and at Memorial Sloan-Kettering Cancer Center in New York City.

    He is the author of more than 160 papers and has contributed numerous textbook chapters on topics related to the biological and clinical significance of genetic changes in neuroblastomas. Dr. Brodeur is also the principal investigator or co- investigator of six NIH/NCI grants studying the genetic basis of neuroblastomas.

  • Education and Training

    Medical School

    MD -Washington University School of Medicine, St. Louis, MO


    Pediatrics - St. Louis Children's Hospital, St. Louis, MO


    Pediatrics - St. Louis Children's Hospital, St. Louis, MO


    Pediatric Hematology-Oncology - St. Jude Children's Research Center, Memphis, TN
    Postdoctoral fellowship in Molecular Genetics - Washington University School of Medicine, St. Louis, MO

    Board Certification

    Pediatric Hematology-Oncology

  • Titles and Academic Titles

    Interim Director, Division of Oncology

    Adjunct professor, The Wistar Institute

    Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Departments and Services
  • Research Interests

    Molecular biology and genetics of human neuroblastoma and genetics of childhood cancer

  • Publications



    Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. Epub 2011 Feb 22. Cited in PubMed: PMID 21340605.  Read the abstract


    Brodeur GM. Getting into the AKT. J Natl Cancer Inst. 2010 Jun 2;102(11):747-9. 2010 Jun 2;102(11):747-9. Epub 2010 May 12. Cited in PubMed: PMID 20463308. Read the article

    Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009 May 15;15(10):3244-50. Epub 2009 May 5. Cited in PubMed: PMID 19417027.  Read the article

    Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009 May 5;100(9):1471-82. Cited in PubMed: PMID 19401703. Read the article

    Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10;27(2):289-97. Epub 2008 Dec 1. Cited in PubMed: PMID 19047291.  Read the article

  • Editorial and Academic Positions

    Editorial positions

    Editorial boards

    1990-present, Cancer and Metastasis Reviews
    1989-present, Genes, Chromosomes and Cancer
    1987-present, Medical and Pediatric Oncology
    1982-present, Cancer Genetics and Cytogenetics

    Academic positions

    Pediatric Oncology Tumor Board: Neuroblastoma, August 2005

    Cancer Pharmacology Course (PHRM 560), U. Penn, Tyrosine kinases as targets for future therapy, February 2006